NHP2 downregulation counteracts hTR-mediated activation of the DNA damage response at ALT telomeres.

DNA Damage / genetics DNA Repair / genetics DNA-Activated Protein Kinase / metabolism Down-Regulation Heterogeneous Nuclear Ribonucleoprotein A1 / metabolism Humans Neoplasms / genetics Nuclear Proteins / biosynthesis RNA / genetics Rad51 Recombinase / metabolism Ribonucleoproteins, Small Nuclear / biosynthesis Telomerase / genetics Telomere / genetics Telomere Homeostasis / physiology
ALT NHP2 RPA hTR telomerase

Journal

The EMBO journal
ISSN: 1460-2075
Titre abrégé: EMBO J
Pays: England
ID NLM: 8208664

Informations de publication

Date de publication:
15 03 2021
Historique:
revised: 15 01 2021
received: 24 07 2020
accepted: 18 01 2021
pubmed: 18 2 2021
medline: 21 10 2021
entrez: 17 2 2021
Statut: ppublish

Résumé

About 10% of cancer cells employ the "alternative lengthening of telomeres" (ALT) pathway instead of re-activating the hTERT subunit of human telomerase. The hTR RNA subunit is also abnormally silenced in some ALT

Identifiants

DOI: 10.15252/embj.2020106336 PMID: 33595114 PMC: PMC7957427
pubmed: 33595114
doi: 10.15252/embj.2020106336
pmc: PMC7957427
doi:

Substances chimiques

Heterogeneous Nuclear Ribonucleoprotein A1 0
NHP2 protein, human 0
Nuclear Proteins 0
Ribonucleoproteins, Small Nuclear 0
hnRNPA1 protein, human 0
telomerase RNA 0
RNA 63231-63-0
DNA-Activated Protein Kinase EC 2.7.11.1
PRKDC protein, human EC 2.7.11.1
RAD51 protein, human EC 2.7.7.-
Rad51 Recombinase EC 2.7.7.-
Telomerase EC 2.7.7.49

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e106336

Informations de copyright

© 2021 The Authors.

Références

Trends Cancer. 2015 Oct 1;1(2):145-156
pubmed: 26645051
Mol Cell Biol. 2017 Sep 26;37(20):
pubmed: 28760773
PLoS One. 2012;7(11):e50062
pubmed: 23185534
Genes (Basel). 2016 Sep 14;7(9):
pubmed: 27649246
Genome Med. 2016 Jun 20;8(1):69
pubmed: 27323951
Mol Cell Biol. 2014 Oct 1;34(19):3662-74
pubmed: 25047840
EMBO Rep. 2011 Dec 23;13(1):52-9
pubmed: 22157895
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Cancer Res. 2005 Sep 1;65(17):7585-90
pubmed: 16140922
EMBO J. 2005 Jun 15;24(12):2161-71
pubmed: 15920481
Blood. 2014 Dec 11;124(25):3675-84
pubmed: 25320237
Trends Biochem Sci. 2015 Sep;40(9):504-15
pubmed: 26188776
Cell Rep. 2015 Dec 15;13(10):2232-43
pubmed: 26628367
Mol Cell. 2011 Apr 22;42(2):224-36
pubmed: 21504833
Mol Cell Biol. 2001 Jun;21(12):3862-75
pubmed: 11359895
EMBO J. 2004 Apr 21;23(8):1857-67
pubmed: 15044956
Cell. 1985 Dec;43(2 Pt 1):405-13
pubmed: 3907856
Front Oncol. 2013 Apr 17;3:91
pubmed: 23616949
Nat Genet. 2000 Dec;26(4):447-50
pubmed: 11101843
EMBO J. 2021 Mar 15;40(6):e106336
pubmed: 33595114
Eur J Cancer. 1997 Apr;33(5):787-91
pubmed: 9282118
Cell Rep. 2019 Jan 22;26(4):955-968.e3
pubmed: 30673617
Nat Rev Mol Cell Biol. 2013 Feb;14(2):69-82
pubmed: 23299958
Oncogene. 1999 Jun 3;18(22):3383-90
pubmed: 10362359
J Cell Biol. 2010 Mar 8;188(5):639-52
pubmed: 20212315
Genes Dev. 2013 Jul 15;27(14):1610-23
pubmed: 23873943
Nature. 1991 Apr 18;350(6319):569-73
pubmed: 1708110
Hum Mutat. 2013 Feb;34(2):374-84
pubmed: 23111928
Cell. 2013 Nov 21;155(5):1088-103
pubmed: 24267891
Mol Cell. 2000 Oct;6(4):947-52
pubmed: 11090632
Science. 2012 May 4;336(6081):593-7
pubmed: 22556254
Nucleic Acids Res. 2014 Apr;42(7):4391-405
pubmed: 24500201
Nat Commun. 2019 May 28;10(1):2252
pubmed: 31138797
Methods. 2017 Feb 1;114:74-84
pubmed: 27595911
Mol Cell. 2017 Jan 19;65(2):336-346
pubmed: 28089683
Cell. 2009 Jan 9;136(1):175-86
pubmed: 19135898
Cancer Res. 1999 Sep 1;59(17):4175-9
pubmed: 10485449
Cell Rep. 2016 Feb 9;14(5):1032-1040
pubmed: 26832416
Nat Cell Biol. 2017 Dec;19(12):1400-1411
pubmed: 29180822
Nucleic Acids Res. 1997 Jul 1;25(13):2595-7
pubmed: 9185569
Mol Cell. 2007 Dec 14;28(5):773-85
pubmed: 18082603
Oncogene. 2002 Jan 21;21(4):598-610
pubmed: 11850785
Histochem Cell Biol. 2015 Dec;144(6):543-58
pubmed: 26265134
Nat Commun. 2019 May 28;10(1):2253
pubmed: 31138795
Nature. 2011 Mar 24;471(7339):532-6
pubmed: 21399625
Hum Mol Genet. 1997 Jun;6(6):921-6
pubmed: 9175740
Cell. 2009 Jul 10;138(1):90-103
pubmed: 19596237
Nat Rev Genet. 2010 May;11(5):319-30
pubmed: 20351727
Genome Res. 2013 Aug;23(8):1195-209
pubmed: 23595228
Nat Struct Mol Biol. 2009 Dec;16(12):1244-51
pubmed: 19935685
Annu Rev Genet. 2008;42:301-34
pubmed: 18680434
BMC Cancer. 2005 Jan 18;5:6
pubmed: 15656906
Am J Pathol. 2011 Oct;179(4):1608-15
pubmed: 21888887
Nucleic Acids Res. 2005 Apr 11;33(7):2090-8
pubmed: 15824061
Nat Biotechnol. 2009 Dec;27(12):1181-5
pubmed: 19935656
Int J Oncol. 2015 Jan;46(1):351-9
pubmed: 25354534
Genes Dev. 2006 Mar 1;20(5):531-6
pubmed: 16481465
J Biol Chem. 2006 Dec 22;281(51):39517-33
pubmed: 17035231
PLoS Genet. 2019 Feb 4;15(2):e1007925
pubmed: 30716077
Cell Rep. 2016 Nov 8;17(7):1858-1871
pubmed: 27829156
Oncogene. 2009 Apr 9;28(14):1682-93
pubmed: 19252523
Nature. 2016 Nov 3;539(7627):54-58
pubmed: 27760120
Int J Mol Sci. 2017 Dec 05;18(12):
pubmed: 29206178
Carcinogenesis. 2005 May;26(5):867-74
pubmed: 15471900
Methods Mol Biol. 2018;1768:513-529
pubmed: 29717462
Cell Rep. 2018 Sep 4;24(10):2629-2642.e5
pubmed: 30184498
Nucleic Acids Res. 2015 Jul 13;43(12):5971-83
pubmed: 25999341
Nucleic Acids Res. 2009 Oct;37(18):6105-15
pubmed: 19656952
Mol Cell. 2019 Aug 8;75(3):469-482.e6
pubmed: 31278054
Science. 2015 Jan 16;347(6219):273-7
pubmed: 25593184
J Cell Sci. 2016 Apr 1;129(7):1468-76
pubmed: 26906421
Nucleic Acids Res. 2010 May;38(9):2955-63
pubmed: 20147462
Nat Rev Mol Cell Biol. 2020 Jul;21(7):384-397
pubmed: 32242127
Proc Natl Acad Sci U S A. 2017 Jul 18;114(29):E5940-E5949
pubmed: 28673972
Retrovirology. 2005 Feb 09;2:8
pubmed: 15703079
Nucleic Acids Res. 2007;35(21):7267-78
pubmed: 17959650
Proc Natl Acad Sci U S A. 2008 Jun 10;105(23):8073-8
pubmed: 18523010
Trends Genet. 2017 Dec;33(12):921-932
pubmed: 28969871
Curr Opin Genet Dev. 2020 Feb;60:1-8
pubmed: 32114293
Nat Rev Mol Cell Biol. 2010 Mar;11(3):171-81
pubmed: 20125188
Cell. 2006 Nov 17;127(4):709-20
pubmed: 17110331
Curr Opin Genet Dev. 2020 Feb;60:25-30
pubmed: 32119936
Carcinogenesis. 2010 Jan;31(1):9-18
pubmed: 19887512
DNA Repair (Amst). 2016 Aug;44:143-150
pubmed: 27283761
J Mol Endocrinol. 2017 Feb;58(2):R129-R146
pubmed: 28057768
J Cell Biol. 2013 Mar 18;200(6):699-708
pubmed: 23479741
Microbiol Mol Biol Rev. 2002 Sep;66(3):407-25, table of contents
pubmed: 12208997
Oncogene. 2019 Aug;38(34):6172-6183
pubmed: 31285550
Cell Rep. 2017 Jun 20;19(12):2529-2543
pubmed: 28636941
Nature. 2012 Aug 9;488(7410):231-5
pubmed: 22722852
J Biol Chem. 2006 Dec 29;281(52):40503-14
pubmed: 17098743
Cancer Res. 1998 Apr 1;58(7):1558-61
pubmed: 9537264
Nat Struct Mol Biol. 2012 Sep;19(9):948-56
pubmed: 22922742
Cell Biosci. 2018 Jan 25;8:5
pubmed: 29416846
Cell. 2014 Sep 25;159(1):108-121
pubmed: 25259924
Hum Mol Genet. 2016 Aug 1;25(15):3255-3268
pubmed: 27427384
Hum Mol Genet. 2020 Apr 15;29(6):907-922
pubmed: 31985013
Genes Dev. 2020 May 1;34(9-10):650-662
pubmed: 32217664

Auteurs

Maya Raghunandan (M)

Genetic and Epigenetic Alterations of Genomes, de Duve Institute, Faculty of Pharmacy and Biomedical Sciences, Université catholique de Louvain, Brussels, Belgium.

Dan Geelen (D)

Genetic and Epigenetic Alterations of Genomes, de Duve Institute, Faculty of Pharmacy and Biomedical Sciences, Université catholique de Louvain, Brussels, Belgium.

Eva Majerova (E)

Genetic and Epigenetic Alterations of Genomes, de Duve Institute, Faculty of Pharmacy and Biomedical Sciences, Université catholique de Louvain, Brussels, Belgium.

Anabelle Decottignies (A)

Genetic and Epigenetic Alterations of Genomes, de Duve Institute, Faculty of Pharmacy and Biomedical Sciences, Université catholique de Louvain, Brussels, Belgium.
ORCID: 0000-0001-7893-2527

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Phénomènes génétiques › Altération de l'ADN › NHP2 downregulation counteracts hTR-mediated...
questionsmedicales.fr › Phénomènes génétiques › Réparation de l'ADN › NHP2 downregulation counteracts hTR-mediated...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines nucléaires › Protéines liant le poly-adp-ribose › DNA-activated protein kinase › NHP2 downregulation counteracts hTR-mediated...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Régulation négative › NHP2 downregulation counteracts hTR-mediated...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Nucléoprotéines › Protéines de liaison à l'ARN › Protéines à motif de reconnaissance de l'ARN › Ribonucléoprotéines nucléaires hétérogènes › Ribonucléoprotéine nucléaire hétérogène du groupe A-B › Ribonucléoprotéine nucléaire hétérogène A1 › NHP2 downregulation counteracts hTR-mediated...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › NHP2 downregulation counteracts hTR-mediated...
questionsmedicales.fr › Tumeurs › NHP2 downregulation counteracts hTR-mediated...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines nucléaires › NHP2 downregulation counteracts hTR-mediated...
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Acides nucléiques › ARN › NHP2 downregulation counteracts hTR-mediated...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines des groupes de complémentation de l'anémie de Fanconi › Rad51 Recombinase › NHP2 downregulation counteracts hTR-mediated...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Nucléoprotéines › Protéines de liaison à l'ARN › Ribonucléoprotéines › Petites ribonucléoprotéines nucléaires › NHP2 downregulation counteracts hTR-mediated...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Nucléoprotéines › Protéines de liaison à l'ARN › Ribonucléoprotéines › Telomerase › NHP2 downregulation counteracts hTR-mediated...
questionsmedicales.fr › Phénomènes génétiques › Structures génétiques › Structures de chromosome › Télomère › NHP2 downregulation counteracts hTR-mediated...
questionsmedicales.fr › Phénomènes physiologiques › Croissance et développement › Croissance › Processus de croissance cellulaire › Prolifération cellulaire › Division cellulaire › Homéostasie des télomères › NHP2 downregulation counteracts hTR-mediated...